Generate Biomedicines Shares Fall Following Q2 Financial Results

Generate Biomedicines Q2 EPS $(0.52) Beats $(0.57) Estimate, Sales $6.314M Miss $6.625M Estimate

Generate Biomedicines - Q2 Revenue $6.30 Mln

Generate Biomedicines: Existing Cash, Cash Equivalents, and Marketable Securities Sufficient to Fund Current Operating Plan into H1 2028

Press Release: Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update

Generate Biomedicines Q2 FY26 Net Loss Widens to $67.26 Million; Revenue Drops to $6.31 Million

Generate Biomedicines Releases Corporate Presentation on Programmable Biology Platform and Clinical-stage Pipeline

Analysts Offer Insights on NA Companies: Yesway Inc Class A (YSWY), Generate Biomedicines, Inc. (GENB) and SK hynix Inc. Sponsored GDR (OtherHXSCL)

Guggenheim Reaffirms Their Buy Rating on Generate Biomedicines, Inc. (GENB)

Generate Biomedicines to present at Goldman Sachs Global Healthcare Conference

Generate Biomedicines publishes corporate presentation on programmable biology drug design platform

Stock Track | Generate Biomedicines Soars 5.29% Intraday Following Nvidia's $10.4 Million Investment

U.S. Small Caps Close Mixed As LiveRamp Holdings Leads, Generate Biomedicines Lags

Generate Biomedicines Is Maintained at Overweight by Morgan Stanley

Generate Biomedicines, Inc. (GENB) Receives a Buy from Morgan Stanley

Morgan Stanley Lifts Price Target on Generate Biomedicines to $22 From $20, Keeps Overweight Rating

Piper Sandler Sticks to Their Buy Rating for Generate Biomedicines, Inc. (GENB)

Generate Biomedicines Is Maintained at Buy by HC Wainwright & Co.